Takeda Pharmaceutical Company Limited (NYSE:TAK) Shares Sold by Bank of New York Mellon Corp

Bank of New York Mellon Corp trimmed its position in Takeda Pharmaceutical Company Limited (NYSE:TAK) by 19.5% during the 2nd quarter, HoldingsChannel reports. The institutional investor owned 89,534 shares of the company’s stock after selling 21,735 shares during the quarter. Bank of New York Mellon Corp’s holdings in Takeda Pharmaceutical were worth $1,159,000 at the end of the most recent reporting period.

Several other large investors also recently bought and sold shares of TAK. Rise Advisors LLC acquired a new stake in shares of Takeda Pharmaceutical in the first quarter worth approximately $26,000. Principal Securities Inc. purchased a new position in Takeda Pharmaceutical in the 4th quarter valued at $28,000. GAMMA Investing LLC boosted its stake in Takeda Pharmaceutical by 50.9% during the 1st quarter. GAMMA Investing LLC now owns 2,864 shares of the company’s stock worth $40,000 after purchasing an additional 966 shares during the last quarter. Blue Trust Inc. grew its holdings in shares of Takeda Pharmaceutical by 74.0% during the second quarter. Blue Trust Inc. now owns 5,480 shares of the company’s stock worth $76,000 after buying an additional 2,330 shares in the last quarter. Finally, Allspring Global Investments Holdings LLC acquired a new stake in shares of Takeda Pharmaceutical in the first quarter valued at about $108,000. 9.17% of the stock is currently owned by hedge funds and other institutional investors.

Takeda Pharmaceutical Stock Performance

TAK opened at $14.80 on Friday. Takeda Pharmaceutical Company Limited has a twelve month low of $12.57 and a twelve month high of $16.06. The firm has a market capitalization of $47.09 billion, a PE ratio of 26.91, a PEG ratio of 0.27 and a beta of 0.54. The company has a current ratio of 1.26, a quick ratio of 0.74 and a debt-to-equity ratio of 0.65. The firm’s 50-day moving average price is $14.32 and its 200 day moving average price is $13.76.

Takeda Pharmaceutical (NYSE:TAK) last issued its earnings results on Wednesday, July 31st. The company reported $0.56 earnings per share for the quarter, topping the consensus estimate of $0.37 by $0.19. Takeda Pharmaceutical had a return on equity of 10.11% and a net margin of 6.02%. The business had revenue of $7.75 billion for the quarter. As a group, sell-side analysts expect that Takeda Pharmaceutical Company Limited will post 1.63 EPS for the current fiscal year.

About Takeda Pharmaceutical

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience.